Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study
Identifieur interne : 004323 ( Main/Exploration ); précédent : 004322; suivant : 004324Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study
Auteurs : Walter Pirker [Autriche] ; Schiva Djamshidian [Autriche] ; Susanne Asenbaum [Autriche] ; Willibald Gerschlager [Autriche] ; Gotthard Tribl [Autriche] ; Martha Hoffmann [Autriche] ; Thomas Brücke [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-01.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Adulte.
English descriptors
- KwdEn :
- Adult, Atypical, Corpus Striatum (metabolism), Corpus Striatum (radionuclide imaging), Degeneration, Disease Progression, Dopamine Plasma Membrane Transport Proteins, Dopaminergic neuron, Evolution, Female, Follow-Up Studies, Humans, Iodine Radioisotopes (diagnostic use), Iodine Radioisotopes (pharmacokinetics), Male, Membrane Glycoproteins, Membrane Transport Proteins (metabolism), Middle Aged, Nerve Degeneration (metabolism), Nerve Degeneration (radionuclide imaging), Nerve Tissue Proteins, Parkinson disease, Parkinson's disease, Parkinsonian Disorders (metabolism), Parkinsonian Disorders (radionuclide imaging), Parkinsonism, Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (pharmacokinetics), Single photon emission tomography, Tomography, Emission-Computed, Single-Photon, [123I]β‐CIT, atypical parkinsonism, disease progression, single photon emission computerized tomography (SPECT).
- MESH :
- chemical , diagnostic use : Iodine Radioisotopes, Radiopharmaceuticals.
- chemical , metabolism : Membrane Transport Proteins.
- chemical , pharmacokinetics : Iodine Radioisotopes, Radiopharmaceuticals.
- chemical : Dopamine Plasma Membrane Transport Proteins, Membrane Glycoproteins, Nerve Tissue Proteins.
- metabolism : Corpus Striatum, Nerve Degeneration, Parkinsonian Disorders.
- radionuclide imaging : Corpus Striatum, Nerve Degeneration, Parkinsonian Disorders.
- Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Tomography, Emission-Computed, Single-Photon.
Abstract
Atypical parkinsonian syndromes (APS) such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration are characterized by poor response to antiparkinsonian medication and rapid clinical deterioration. We used SPECT and [123I]β‐CIT as a label of dopamine transporters to study the progression of presynaptic dopaminergic degeneration in Parkinson's disease (PD) and APS. Twenty‐four PD patients with short disease duration (2.4 ± 1.5 years), 12 PD patients with long disease duration (9.2 ± 2.6 years), 10 patients with APS (disease duration 2.1 ± 1.5 years), and nine patients with essential tremor (ET) underwent sequential [123I]β‐CIT SPECT imaging with an interval of 25.5 ± 10.3 (13–63) months. The age‐related decline of striatal β‐CIT binding was studied cross‐sectionally in 30 healthy subjects. The ratio of striatum/cerebellum −1 at 20 hours after tracer injection, reflecting specific‐to‐nondisplaceable binding, was used as the primary SPECT outcome measure. At scan 1, striatal β‐CIT binding was reduced in PD patients with short disease duration (−42% compared with age‐corrected normal values) and long disease duration (−51%), and APS (−36%), but normal in ET. During the observation period striatal β‐CIT binding significantly declined in patients with APS (14.9% per year) and short duration PD (7.1% per year), whereas PD patients with long disease duration and patients with ET showed no significant change of striatal β‐CIT binding between scans 1 and 2. The relative annual reduction from age‐corrected normal values at the time of scan 1 was significantly higher in patients with APS than in PD patients with short disease duration (9.6 vs. 4.3%, P = 0.004). These results demonstrate a rapid decline of striatal β‐CIT binding in patients with atypical parkinsonian syndromes, exceeding the reduction in PD. The dopaminergic degeneration in PD appears to slow down during the course of the disease. SPECT with [123I]β‐CIT is a sensitive marker of disease progression in parkinsonian disorders. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1265
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000061
- to stream Istex, to step Curation: 000061
- to stream Istex, to step Checkpoint: 002C14
- to stream Main, to step Merge: 006328
- to stream PascalFrancis, to step Corpus: 002851
- to stream PascalFrancis, to step Curation: 000470
- to stream PascalFrancis, to step Checkpoint: 002638
- to stream Main, to step Merge: 006677
- to stream PubMed, to step Corpus: 003C00
- to stream PubMed, to step Curation: 003C00
- to stream PubMed, to step Checkpoint: 003966
- to stream Ncbi, to step Merge: 000651
- to stream Ncbi, to step Curation: 000651
- to stream Ncbi, to step Checkpoint: 000651
- to stream Main, to step Merge: 006134
- to stream Main, to step Curation: 004323
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study</title>
<author><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name>
</author>
<author><name sortKey="Djamshidian, Schiva" sort="Djamshidian, Schiva" uniqKey="Djamshidian S" first="Schiva" last="Djamshidian">Schiva Djamshidian</name>
</author>
<author><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name>
</author>
<author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name>
</author>
<author><name sortKey="Tribl, Gotthard" sort="Tribl, Gotthard" uniqKey="Tribl G" first="Gotthard" last="Tribl">Gotthard Tribl</name>
</author>
<author><name sortKey="Hoffmann, Martha" sort="Hoffmann, Martha" uniqKey="Hoffmann M" first="Martha" last="Hoffmann">Martha Hoffmann</name>
</author>
<author><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:481AC96D1ED99B5ED7BE0F0997B993014BCB7652</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.1265</idno>
<idno type="url">https://api.istex.fr/document/481AC96D1ED99B5ED7BE0F0997B993014BCB7652/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000061</idno>
<idno type="wicri:Area/Istex/Curation">000061</idno>
<idno type="wicri:Area/Istex/Checkpoint">002C14</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Pirker W:progression:of:dopaminergic</idno>
<idno type="wicri:Area/Main/Merge">006328</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:02-0204551</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002851</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000470</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002638</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Pirker W:progression:of:dopaminergic</idno>
<idno type="wicri:Area/Main/Merge">006677</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11835438</idno>
<idno type="wicri:Area/PubMed/Corpus">003C00</idno>
<idno type="wicri:Area/PubMed/Curation">003C00</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003966</idno>
<idno type="wicri:Area/Ncbi/Merge">000651</idno>
<idno type="wicri:Area/Ncbi/Curation">000651</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000651</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Pirker W:progression:of:dopaminergic</idno>
<idno type="wicri:Area/Main/Merge">006134</idno>
<idno type="wicri:Area/Main/Curation">004323</idno>
<idno type="wicri:Area/Main/Exploration">004323</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study</title>
<author><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Djamshidian, Schiva" sort="Djamshidian, Schiva" uniqKey="Djamshidian S" first="Schiva" last="Djamshidian">Schiva Djamshidian</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Wilhelminenspital, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Nuclear Medicine, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tribl, Gotthard" sort="Tribl, Gotthard" uniqKey="Tribl G" first="Gotthard" last="Tribl">Gotthard Tribl</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hoffmann, Martha" sort="Hoffmann, Martha" uniqKey="Hoffmann M" first="Martha" last="Hoffmann">Martha Hoffmann</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Nuclear Medicine, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Wilhelminenspital, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-01">2002-01</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="45">45</biblScope>
<biblScope unit="page" to="53">53</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">481AC96D1ED99B5ED7BE0F0997B993014BCB7652</idno>
<idno type="DOI">10.1002/mds.1265</idno>
<idno type="ArticleID">MDS1265</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Atypical</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus Striatum (radionuclide imaging)</term>
<term>Degeneration</term>
<term>Disease Progression</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Dopaminergic neuron</term>
<term>Evolution</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Iodine Radioisotopes (diagnostic use)</term>
<term>Iodine Radioisotopes (pharmacokinetics)</term>
<term>Male</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins (metabolism)</term>
<term>Middle Aged</term>
<term>Nerve Degeneration (metabolism)</term>
<term>Nerve Degeneration (radionuclide imaging)</term>
<term>Nerve Tissue Proteins</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Parkinsonian Disorders (metabolism)</term>
<term>Parkinsonian Disorders (radionuclide imaging)</term>
<term>Parkinsonism</term>
<term>Radiopharmaceuticals (diagnostic use)</term>
<term>Radiopharmaceuticals (pharmacokinetics)</term>
<term>Single photon emission tomography</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>[123I]β‐CIT</term>
<term>atypical parkinsonism</term>
<term>disease progression</term>
<term>single photon emission computerized tomography (SPECT)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Iodine Radioisotopes</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Transport Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Iodine Radioisotopes</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Membrane Glycoproteins</term>
<term>Nerve Tissue Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term>
<term>Nerve Degeneration</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Corpus Striatum</term>
<term>Nerve Degeneration</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adulte</term>
<term>Atypique</term>
<term>Dégénérescence</term>
<term>Evolution</term>
<term>Neurone dopaminergique</term>
<term>Parkinson maladie</term>
<term>Parkinsonisme</term>
<term>Tomoscintigraphie émission monophotonique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="fr">Atypical parkinsonian syndromes (APS) such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration are characterized by poor response to antiparkinsonian medication and rapid clinical deterioration. We used SPECT and [123I]β‐CIT as a label of dopamine transporters to study the progression of presynaptic dopaminergic degeneration in Parkinson's disease (PD) and APS. Twenty‐four PD patients with short disease duration (2.4 ± 1.5 years), 12 PD patients with long disease duration (9.2 ± 2.6 years), 10 patients with APS (disease duration 2.1 ± 1.5 years), and nine patients with essential tremor (ET) underwent sequential [123I]β‐CIT SPECT imaging with an interval of 25.5 ± 10.3 (13–63) months. The age‐related decline of striatal β‐CIT binding was studied cross‐sectionally in 30 healthy subjects. The ratio of striatum/cerebellum −1 at 20 hours after tracer injection, reflecting specific‐to‐nondisplaceable binding, was used as the primary SPECT outcome measure. At scan 1, striatal β‐CIT binding was reduced in PD patients with short disease duration (−42% compared with age‐corrected normal values) and long disease duration (−51%), and APS (−36%), but normal in ET. During the observation period striatal β‐CIT binding significantly declined in patients with APS (14.9% per year) and short duration PD (7.1% per year), whereas PD patients with long disease duration and patients with ET showed no significant change of striatal β‐CIT binding between scans 1 and 2. The relative annual reduction from age‐corrected normal values at the time of scan 1 was significantly higher in patients with APS than in PD patients with short disease duration (9.6 vs. 4.3%, P = 0.004). These results demonstrate a rapid decline of striatal β‐CIT binding in patients with atypical parkinsonian syndromes, exceeding the reduction in PD. The dopaminergic degeneration in PD appears to slow down during the course of the disease. SPECT with [123I]β‐CIT is a sensitive marker of disease progression in parkinsonian disorders. © 2001 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Vienne (Autriche)</li>
</region>
<settlement><li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name>
</region>
<name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name>
<name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name>
<name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name>
<name sortKey="Djamshidian, Schiva" sort="Djamshidian, Schiva" uniqKey="Djamshidian S" first="Schiva" last="Djamshidian">Schiva Djamshidian</name>
<name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name>
<name sortKey="Hoffmann, Martha" sort="Hoffmann, Martha" uniqKey="Hoffmann M" first="Martha" last="Hoffmann">Martha Hoffmann</name>
<name sortKey="Tribl, Gotthard" sort="Tribl, Gotthard" uniqKey="Tribl G" first="Gotthard" last="Tribl">Gotthard Tribl</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004323 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004323 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:481AC96D1ED99B5ED7BE0F0997B993014BCB7652 |texte= Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study }}
This area was generated with Dilib version V0.6.23. |